-

Monsanto Wins Third Circuit Court of Appeals Ruling in Schaffner v. Monsanto

Decision presents pathway to take preemption argument to U.S. Supreme Court

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, the Third Circuit Court of Appeals issued its ruling in Monsanto’s favor in the Schaffner v. Monsanto case, unanimously finding that the state-based failure-to-warn claims in this case are expressly preempted by the FIFRA statute.

This decision creates a circuit split with prior decisions of the Ninth and Eleventh Circuits on the central legal issues in the Roundup litigation and underscores the need for consistency on this important topic from a federal standpoint.

In response to the Schaffner v. Monsanto ruling, Monsanto issued the following statement:

“The Company is pleased with the unanimous decision from the Third Circuit holding that plaintiff’s state-based warning claims are expressly preempted by FIFRA. The Court concluded that ‘the alleged state-law duty to include the Cancer Warning on Roundup’s label imposes requirements that are different from those imposed under FIFRA, and that it is therefore preempted by FIFRA.”

“This decision on federal preemption, a cross-cutting issue in this litigation, creates a circuit split among the federal appellate courts and necessitates a review by the U.S. Supreme Court to settle this important issue of law. The Company is considering the impact of this ruling on other pending litigation and looks forward to presenting its arguments, as fully embraced by the Third Circuit, to the U.S. Supreme Court.”

“Bayer continues to stand fully behind its Roundup™ products – critical tools that farmers rely on to produce affordable food and feed the world – as the weight of scientific evidence and the conclusions of expert regulators worldwide continue to support the safety of glyphosate-based herbicides and that they are not carcinogenic.”

Contacts

Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Monsanto


Release Versions

Contacts

Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Monsanto

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigat...

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalance between estrogen and progesterone levels. This condition is classified as nonatypical as the cells...
Back to Newsroom